Review article · 2014
Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival
Gynecologic Oncology, 136(1), 121–129 · Published 25 October 2014 · DOI 10.1016/j.ygyno.2014.10.010
In brief
“Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival” is a 2014 review article by James Tate Thigpen, published in Gynecologic Oncology. OpenAlex counts 15 citations as of 22 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 15
- Most cited in
- 2017 (3)
- Field-weighted impact
- 0.27
- References
- 66
- Authors
- 1
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Thigpen, J. T. (2014). Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival. Gynecologic Oncology, 136(1), 121–129. https://doi.org/10.1016/j.ygyno.2014.10.010
MLA 9
Thigpen, James Tate. “Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.” Gynecologic Oncology, vol. 136, no. 1, 2014, pp. 121–129. https://doi.org/10.1016/j.ygyno.2014.10.010.
Chicago
Thigpen, James Tate. 2014. “Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.” Gynecologic Oncology 136 (1): 121–129. https://doi.org/10.1016/j.ygyno.2014.10.010.
Harvard
Thigpen, J. T. (2014) ‘Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival’, Gynecologic Oncology, 136(1), pp. 121–129. doi:10.1016/j.ygyno.2014.10.010.
IEEE
J. T. Thigpen, “Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival,” Gynecologic Oncology, vol. 136, no. 1, pp. 121–129, 2014, doi: 10.1016/j.ygyno.2014.10.010.
BibTeX
@article{thigpen2014contemporary,
title = {{Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival}},
author = {Thigpen, James Tate},
journal = {Gynecologic Oncology},
year = {2014},
volume = {136},
number = {1},
pages = {121--129},
doi = {10.1016/j.ygyno.2014.10.010},
url = {https://doi.org/10.1016/j.ygyno.2014.10.010}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2015 | 2 | |
| 2016 | 2 | |
| 2017 | 3 | |
| 2018 | 1 | |
| 2019 | 1 | |
| 2020 | 1 | |
| 2023 | 2 | |
| 2024 | 1 | |
| 2025 | 1 | |
| 2026 | 1 |
Its field-weighted citation impact is 0.27: it has been cited 0.27 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- advanced ovarian cancer
- clinical trial endpoints
- objective response rate
- progression-free survival
- overall survival
- post-progression therapy
- RECIST
- surrogate endpoints
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Thigpen, J. T. (2014). Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival. Gynecologic Oncology, 136(1), 121–129. https://doi.org/10.1016/j.ygyno.2014.10.010
How many times has this paper been cited?
15 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
James Tate Thigpen.
What is the DOI of this paper?
10.1016/j.ygyno.2014.10.010, permanently at https://doi.org/10.1016/j.ygyno.2014.10.010. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.